Capsaicinoids

Capsaicinoids

1. Identity: Botanical Source, Chemistry, and Forms

Botanical Origin and Taxonomy

Capsaicinoids are a group of important compounds that are particularly synthesized by various members of the genus Capsicum in their placenta. The genus Capsicum belongs to the Solanaceae family and is a diverse genus consisting of more than 31 different species, including five domesticated species: Capsicum baccatum, C. annuum, C. pubescens, C. frutescens, and C. chinense. The chili pepper Capsicum annuum L., which belongs to the family Solanaceae in the class Magnoliopsida, is an annual or limited perennial herb widely used globally as a medicinal and edible plant.

Chemical Identity

The most prominent pungent principle in the hot peppers of the genus Capsicum is capsaicin (8-methyl-N-vanillyl-6-nonenamide), an organic nitrogenous compound within the lipid group. The name "capsaicin" was originally used to refer to a multitude of substances originally isolated from C. oleoresin; these compounds are now known as capsaicinoids, a distinction made after the 1960s.

Capsaicin is the most abundant vanilloid compound among the different capsaicinoids in hot peppers. Other capsaicinoids include dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and homodihydrocapsaicin. More precisely, capsaicin exists as a family of compounds including capsaicin, dihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, nordihydrocapsaicin, capsaicin esters, dihydrocapsaicin esters, nordihydrocapsaicin esters, capsanthin-β-d-glucoside, and dihydrocapsanthin-β-d-glucoside. Among them, capsaicin and dihydrocapsaicin are the most abundant compounds responsible for the pungency of the fruits.

Structurally, capsaicinoids may be generally classified as acid amide derivatives of phenol. The vanillyl structure on which the capsaicinoids are constructed is also typical of the pungent principals found in ginger (Zingiberacea) species of plants. The hotness of the various capsicums is directly attributable to their capsaicinoid content.

Quantification: The Scoville Scale

Pungency is conventionally expressed in Scoville Heat Units (SHU). Cayenne pepper, quite hot to human taste, is approximately 30,000 to 50,000 units on the Scoville scale. By comparison, habanero pepper's relative heat ranges from 200,000 to 300,000 Scoville Units; research has shown it may contain approximately 0.013 g of capsaicin per gram of capsicum. Approximately 3 mg of capsaicinoids are present in 1 g of dried red chilli pepper.

Preparation Forms

Capsaicin is administered in many forms such as low-concentration creams, lotions, patches, intradermal injections, oral formulations, subcutaneous injections, intravenous preparations, films, microemulsions, liposomes, and nanotechnology-derived drug delivery systems. For topical applications, capsaicin is typically used in concentrations ranging from 0.025% to 0.1%, with higher concentrations being used under medical supervision for neuropathic pain; the formulation can come in the form of creams, gels, or patches, which provide sustained release over the course of time.

2. Traditional and Historical Use

Mesoamerican Origins

Capsaicin is a common component found in the fruits of the genus Capsicum plants, which have been known to humanity and consumed in food for approximately 7,000–9,000 years. It has been discovered that the cultivation of chilli peppers began around the 5th millennium BC, rendering them among the oldest cultivated plants; their origin is estimated to be somewhere in Bolivia. The consumption of chili peppers dates back to 7000 B.C. in Mesoamerica.

The similarity of the oral irritation of black pepper and the chili peppers of the New World led to the name "pepper" for the chilis, although they are not botanically related to the black pepper; chili peppers are botanically related to the tomato, potato, tobacco, and nightshade.

Traditional Medicinal Uses

The plant-origin capsaicinoids (capsaicin, dihydrocapsaicin, norcapsaicin, dihydrocapsaicin, homocapsaicin, homodihydrocapsaicin) are well known and have been used as nutritional additive agents in everyday nutritional practice from the last 9,500 years. The fruit is used in the traditional medicines of China and other countries for warming the body, "dispelling cold," and promoting digestion. Interestingly, Capsicum fruits have been used as food additives in the treatment of toothache, parasitic infections, coughs, wound healing, sore throat, and rheumatism.

Chilli peppers came to Europe only after the discovery of the New World and the subsequent Columbian Exchange; they were swiftly adopted by many cultures and, as such, are ingredients in many local and traditional dishes. Capsaicin, the most prominent pungent compound of chilli peppers, has been used in traditional medicine systems for centuries and already has a number of established clinical and industrial applications.

This pungent alkaloid in Capsicum species is the major bioactive compound and has been broadly explored from a pharmacological perspective; additional data are available on the exploitation of capsaicinoids in various biological activities, including anti-inflammatory, anti-lithogenic, and cardioprotective applications.

Scientific Knowledge Timeline

Scientific knowledge about capsaicinoids' chemistry, physiology, and pharmacology became evidence-based from the year 1980, dominantly in animal observations; human observations with capsaicinoids, in terms of good clinical practice, began only in the late 1990s in randomized, prospective, multiclinical studies.

3. Key Constituents and Active Compounds

Principal Capsaicinoids

The capsaicinoid class encompasses several structurally related vanillyl amides. The primary compounds and their characteristics are:

• Capsaicin — The dominant capsaicinoid by abundance; molecular formula C₁₈H₂₇NO₃; chemical name 8-methyl-N-vanillyl-6-nonenamide. For heat production, capsaicin appears to be the most important of the capsaicinoids and is a principal active ingredient of cayenne pepper.
• Dihydrocapsaicin — Among the capsaicinoids, capsaicin and dihydrocapsaicin are the most abundant compounds responsible for the pungency of the fruits. Dihydrocapsaicin (DHC) has demonstrated neuroprotective qualities; this pungent capsaicinoid is present in hot peppers in significant amounts.
• Nordihydrocapsaicin, Homocapsaicin, Homodihydrocapsaicin — Present in smaller quantities; the term "capsaicins" is intended to encompass homocapsaicin, nordihydrocapsaicin, dihydrocapsaicin, homodihydrocapsaicin, or any compounded mixture thereof.

Other Phytochemicals in Capsicum

Pepper is a good source of provitamin A; vitamins E and C; carotenoids; and phenolic compounds such as capsaicinoids, luteolin, and quercetin. The fruit contains various active components, including capsaicin, which is the most abundant pungent compound; capsaicinoids and carotenoids.

4. Mechanisms of Action

The TRPV1 Receptor: Primary Molecular Target

Some of the effects of capsaicin are mediated by the receptor called "transient receptor potential cation channel subfamily V member 1" (TRPV1), to which capsaicin binds specifically. TRPV1 is a Ca²⁺-selective member of the family of transient receptor potential ion channels, which sense heat. TRPV1 is broadly distributed in tissues of the brain, bladder, kidneys, intestines, epidermal keratinocytes, glial cells, liver, polymorphonuclear granulocytes, mast cells, and macrophages.

Capsaicin is an agonist of TRPV1 that reduces its activation threshold. Capsaicin specifically activates transient receptor potential vanilloid subtype 1 (TRPV1), a Ca²⁺-permeable ion channel. Capsaicin is known to act through the TRPV1 receptor, which exists in various tissues; capsaicin is hepatically metabolised, having a half-life correlated with the method of application.

Most of the biological effects of capsaicin — and other capsaicinoids — are associated with activation of the capsaicin (TRPV1) receptor; however, some biological activities, like its anti-neoplastic and cardioprotective effects, have been found to be independent of the TRPV1 receptor.

Desensitization and "Defunctionalization"

After TRPV1 has been activated by capsaicin, the receptor enters a long-lasting refractory state, in which it does not respond to mechanical pressure, pain, or inflammatory agents. This so-called "defunctionalization" results from the closing of the channel pore due to conformational changes that depend on extracellular Ca²⁺. To what extent this transient "defunctionalization" explains the observed analgesic effects of capsaicin remains unclear. When activated by capsaicin, TRPV1 mediates Ca²⁺ influx and glutamate release, which may damage cutaneous autonomic nerve fibers and sensory nerve endings, decreasing pain sensation.

Repeated application or single exposure to high-concentration capsaicin causes over-stimulation and subsequent desensitization of TRPV1 receptors, depletion of substance P, and a reversible degeneration of sensory nerves. Binding at the TRPV1 channel leads to an initial activation and sensitization of nociceptors, associated with the release of neuropeptides such as substance P from their central and peripheral terminals, resulting in painful responses. When a sensory neuron is exposed to capsaicin, it releases its supply of substance P, and upon repeated application, stops producing substance P; the neuron's ability to send a pain signal is thereby diminished. After topical application of capsaicin is discontinued, substance P stores revert to pretreatment levels, and neuronal sensitivity returns to normal.

Although capsaicin's analgesic effect was thought to be due to a depletion in the pain-causing substance P, recent evidence suggests a process of "defunctionalization" of nociceptor fibers is responsible for its analgesic effect.

Thermogenic Mechanism

Capsaicinoids, naturally present in chili fruits (Capsicum), have been established as thermogenic molecules stimulating energy expenditure and lipolysis by activation of TRPV1. Both capsaicin and the non-pungent analog dihydrocapsiate stimulate TRPV1 receptors in the gut, which bring about activation of the sympathetic nervous system, which can increase lipogenesis and thermogenesis. These findings support the concept that capsaicin and related compounds can enhance human energy expenditure, primarily through activation of brown and beige adipose thermogenesis, with TRPV1 serving as a key but context-dependent mediator.

Cardiovascular Mechanisms

Capsaicin activates TRPV1 receptors in endothelial cells, stimulating nitric oxide release, thereby opening blood vessels and improving circulation. Capsaicin itself has been proposed to exhibit vasodilatory properties; however, a growing body of evidence also reveals a vasoconstrictory potential of capsaicin acting via the vascular TRPV1 channel, suggesting that unnecessarily high consumption may cause adverse effects.

Anti-Cancer Mechanisms (Preclinical)

Capsaicin exhibits interesting anticancer potential in different preclinical studies by targeting cancer cells through promoting apoptosis, inhibiting angiogenesis, and modulating cell cycle regulators; it interacts with intracellular pathways to increase oxidative stress and disrupt mitochondrial function, selectively damaging malignant cells while sparing normal ones.

Antioxidant Mechanisms

Adults who received capsaicin for 4 weeks demonstrated lower levels of oxidation of serum lipoproteins; in mitochondria, capsaicin can reduce lipid peroxidation and, more generally, oxidative stress; it can alleviate ischemia-reperfusion injury in myocardium and kidney; most of these antioxidant effects appear to be mediated by TRPV1.

5. Scientific Evidence by Area of Use

5.1 Pain Management: Neuropathic Pain

This is the best-supported clinical application of capsaicin, with regulatory approval in multiple jurisdictions. Topical capsaicin is an FDA-approved treatment for neuropathic pain. The high-concentration (179 mg) capsaicin patch (known as capsaicin 8% topical system in the United States) provides a topical treatment option for peripheral neuropathic pain in adults and may be used as monotherapy or in combination with other pain medications. In the European Union, it is indicated for peripheral neuropathic pain of any cause, whereas in the United States its indication is limited to the treatment of postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (PDPN).

A single, one-hour-long application of a high-dose capsaicin patch approved by the FDA proves to significantly reduce pain in patients suffering from postherpetic neuralgia and maintains its analgesic effect for up to three months; the Qutenza patch (NeurogesX) is a novel medical treatment containing 8 percent capsaicin and is designed for the topical management of neuropathic pain associated with postherpetic neuralgia.

In a meta-analysis examining 2,057 persons with PHN and HIV-associated neuropathy, the proportion of responders with relief (greater than 30% improvement in pain lasting from 2–12 weeks) over a 12-week treatment period was 43% in the capsaicin 8% patch group and 34% in the control group, a statistically significant difference.

In a systematic review, capsaicin 0.075% cream demonstrated statistically significant benefit in postherpetic neuralgia, postsurgical neuropathies, and diabetic neuropathy compared to placebo; the analgesic effect of capsaicin 0.075% cream has been demonstrated throughout 4–12 weeks of study follow-up, although it may take weeks of application to achieve significant benefit.

The efficacy of the single high-dose capsaicin 8% patch has been observed up to 12 weeks in published data; it is effective for postherpetic neuralgia, but there have been mixed results with the patch for HIV-related neuropathy; and to date no head-to-head trials have compared the capsaicin 8% patch to capsaicin 0.075% cream.

A single application of high-concentration capsaicin for 60 minutes for postherpetic neuralgia has been robustly evaluated; capsaicin 8% patches are applied to the most painful areas of healthy skin and allowed to remain for 60 minutes; treatment can be repeated every 90 days if the pain persists or returns; the patches are usually applied in specialist pain clinics where patients can be pre-treated and monitored.

Capsaicin patch (8%) was found to be as effective as oral medications in treating painful diabetic peripheral neuropathy but without the adverse effects such as somnolence, dizziness, and fatigue associated with oral medications.

Evidence strength: Strong for postherpetic neuralgia (high-dose patch, multiple RCTs, FDA-approved); moderate for other neuropathies. The low-concentration cream evidence is weaker overall, with compliance issues noted due to burning sensation and frequent application requirements.

5.2 Pain Management: Musculoskeletal and Osteoarthritis

Topical, low-concentration capsaicin has been evaluated as a treatment for osteoarthritis (OA) in multiple double-blind vehicle-controlled clinical trials; clinical studies of these medications, usually involving three to five topical skin applications per day for periods of 2–6 weeks, have generally suggested modest beneficial effects against various pain syndromes, including postherpetic neuralgia, diabetic neuropathy, and chronic musculoskeletal pain.

Results suggest modest beneficial effects on different kinds of pain such as diabetic neuropathy, postherpetic neuralgia, chronic musculoskeletal pain, and arthritis-related pains. Although studies demonstrate its effectiveness in musculoskeletal pain, capsaicin 0.025% cream has not been adequately studied for neuropathic pain.

Poor patient compliance is often cited as a likely contributor to limited efficacy for low-concentration products, because each application may be associated with a burning sensation.

Topical capsaicin, an FDA-approved treatment for neuropathic pain, addresses pain from abnormal nociceptor activity in the superficial layers of the skin; effects after a single administration are evident over a period of weeks to months but in time are fully reversible; injectable capsaicin has been evaluated for conditions such as osteoarthritis and shows promise in clinical studies.

Evidence strength: Moderate for osteoarthritis (multiple RCTs and systematic reviews demonstrate modest benefit); limited by small study sizes, heterogeneous study designs, and compliance issues.

5.3 Thermogenesis and Weight Management

A systematic review and meta-analysis was carried out to examine the effect of capsaicinoids/capsinoids on thermogenesis indices; of 4,092 articles, 13 studies were included; pooled effect sizes revealed that compared with placebo, capsaicinoids/capsinoids significantly increased resting metabolic rate (RMR) (weighted mean difference: 33.99 kcal/day, 95% CI: 15.95–52.03; I²: 0%), energy expenditure, and fat oxidation; they also significantly lessened respiratory quotient (RQ) (WMD: −0.01, 95% CI: −0.02 to −0.01) and carbohydrate oxidation.

Intervention in capsule form for longer duration had a more considerable influence on RMR than comparative groups. One clinical study showed that 9 mg of capsinoid for 8 weeks could increase brown adipose tissue (BAT) activity and increase thermogenesis in healthy subjects.

Longer-term capsinoid supplementation increases brown adipose tissue vascular density and resting energy expenditure in healthy middle-aged adults; meta-analyses of clinical trials also show modest but significant increases in resting metabolic rate and fat oxidation, particularly in individuals with overweight or obesity.

Capsaicin from chili pepper is known to stimulate thermogenesis through a central nervous mechanism, but at doses required to observe this metabolic effect, intolerable gastrointestinal side effects occur; studies suggest that capsinoids such as dihydrocapsiate, found in the non-pungent CH-19 sweet pepper, share the positive metabolic characteristics of capsaicin without inducing gastrointestinal side effects.

Despite compelling mechanistic and preclinical evidence, clinical translation of capsaicin-based interventions remains constrained by variability in dosing, bioavailability, and interindividual responsiveness.

There is little scientific proof it works as a weight-loss agent or lowers blood sugar, although more studies need to be done to evaluate its total effect on delaying obesity-related metabolic syndrome.

Evidence strength: Modest and consistent for short-term increases in resting metabolic rate (~34 kcal/day) and fat oxidation (meta-analysis level); effects on body weight and adiposity are statistically significant but clinically small and may not be relevant long-term without dietary restriction. This area has conflicting assessments across authoritative sources.

5.4 Lipid Profile and Cardiometabolic Effects

A systematic review and meta-analysis identifying nine randomized controlled trials including 461 patients found that capsaicin significantly decreased total cholesterol (TC) (WMD = −0.48, 95% CI: −0.63 to −0.34; I² = 0.00%) and LDL cholesterol (WMD = −0.23, 95% CI: −0.45 to −0.02; I² = 68.27%) among patients with metabolic syndrome; no significant effects were found on triglycerides or HDL cholesterol.

Red pepper/capsaicin supplementation may yield modest benefits in reducing total cholesterol and diastolic blood pressure; however, sensitivity analysis demonstrated that the significant results for total cholesterol and diastolic blood pressure were dependent on a single study.

The lipid-lowering, antihypertensive, antidiabetic, and anti-obesity effects of C. annuum have been demonstrated in several studies; according to these studies, red pepper as well as capsaicin has ability to control metabolic syndrome and its related disorders such as obesity, disrupted lipid profile, diabetes, and its complications.

Evidence strength: Preliminary to moderate for lipid-lowering and blood pressure effects in metabolic syndrome patients (evidence base of 9 RCTs); many effects are heavily reliant on single-study findings and high heterogeneity exists. Most evidence comes from animal models, with limited robust human data.

5.5 Gastrointestinal Effects

Numerous studies have revealed that capsaicin acts on the gastrointestinal (GI) tract in TRPV1-dependent and -independent manners, mostly depending on its consumption concentrations. Although high-dose intake of dietary capsaicin is harmful to human health in some cases, current literature suggests that appropriate-dose intake is likely beneficial to GI health and is preventive/therapeutic to GI disease in most cases.

Previous studies have attributed several positive gastrointestinal effects to capsaicin: it induces the release of calcitonin gene-related peptide, activates gastroprotective cyclooxygenase-1, and increases the absorptive surface of the small intestine. A low dose of capsaicin and its natural homologs and analogs (capsaicinoids) have been shown to prevent development of gastric mucosal damage from alcohol and non-steroidal anti-inflammatory drugs.

Capsaicinoids are able to modify capsaicin-sensitive afferent nerves, which have principal roles in the defence of the gastrointestinal tract against damage from chemicals, heat, stretch, and chemical milieu.

Evidence strength: Largely based on animal and in vitro studies. While mechanistic evidence is compelling, robust controlled human clinical trials specifically assessing GI protection are limited. The paradoxical dose-dependent relationship (gastroprotective at low doses; potentially irritating at high doses) is an important consideration.

5.6 Cardiovascular System

Capsaicin indicates cardioprotective attributes, specifically in regulating blood pressure, lipid metabolism, and vascular health. Long-term consumption of capsaicin can reduce blood pressure in spontaneously hypertensive rats and can prevent nocturnal hypertension in mice caused by a high-salt diet. Capsaicin favorably influences lipid homeostasis by inhibiting lipogenesis, promoting fatty acid oxidation, and improving cholesterol handling, collectively contributing to vascular protection.

Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a natural vanilloid, has been studied in the treatment of various cardiovascular diseases.

Evidence strength: Primarily animal and in vitro evidence; a small number of human RCTs exist with modest, sometimes single-study-dependent results. Large-scale prospective human trials specifically for cardiovascular endpoints are lacking.

5.7 Anti-Cancer Effects

Various teams have documented capsaicin's anti-cancer effects, proven in both in vivo and in vitro designs. Capsaicin exhibits anticancer potential in different preclinical studies involving various pathways related to tumor formation and development; it targets cancer cells by promoting apoptosis, inhibiting angiogenesis, and modulating cell cycle regulators.

Epidemiological and laboratory data have suggested that capsaicin can act as either a carcinogen or an anticarcinogen, and this is an area of ongoing debate. Capsaicin appears to interact with xenobiotic-metabolizing enzymes, particularly microsomal cytochrome P450-dependent monooxygenases, which are involved in activation as well as detoxification of various chemical carcinogens and mutagens.

Evidence strength: Largely preclinical (in vitro and animal models). No robust human clinical trials establishing anti-cancer efficacy have been published to date. The dual potential as carcinogen/anticarcinogen depending on dose and context underscores the need for caution in extrapolating preclinical findings to human recommendations.

5.8 Urinary Bladder and Other Clinical Areas

A large number of pharmacological studies have used capsaicin to activate many physiological systems, with an emphasis on pain research but also including functions such as the cardiovascular system, the respiratory system, and the urinary tract.

Clinical conditions for which capsaicin has been investigated include: osteoarthritis, chronic musculoskeletal pain, post-mastectomy pain syndrome, burning mouth syndrome, overactive bladder, gastropathy, postoperative nausea and vomiting, pruritus, pruritus ani, postoperative sore throat, improving cough reflex sensitivity in patients with a history of dysphagia and other swallowing-related disorders, and chemotherapy- and radiotherapy-induced mucositis.

Evidence strength: Variable and generally preliminary or weak for most of these additional indications; some (e.g., overactive bladder) have small proof-of-concept human studies, while others remain largely at the case-report or animal-study stage.

6. Dosage Forms and Dosages Reported in Clinical Studies

Topical Forms

In addition to the high-dose patch, capsaicin is commercially available as 0.025%, 0.075%, and 0.1% creams; these creams are applied by patients or caregivers 3–4 times per day.

Depletion of substance P does not occur immediately; effective use of the cream at 0.075% capsaicin requires topical application 4 or 5 times daily for a period of at least 4 weeks.

The recommended dose of Qutenza for neuropathic pain associated with postherpetic neuralgia is a single, 60-minute application of up to four patches. Treatment can be repeated every 90 days if the pain persists or returns.

Oral Forms

One clinical study showed that 9 mg of capsinoid (a non-pungent capsaicin analog) for 8 weeks could increase brown adipose tissue activity and increase thermogenesis in healthy subjects.

Bioavailability

Because of its chemical structure, capsaicin can be well absorbed when administered topically or orally, reaching up to 94% of absorption and a maximum concentration of 1.90 µg/ml in the blood as observed 1 hour after oral administration in rats at a dose of 30 mg/kg body weight. Systemic absorption from the high-dose patch is minimal and clinically insignificant.

7. Safety Considerations and Interactions

General Local and Systemic Adverse Effects

Common adverse effects of the capsaicin 8% patch are transient mild-to-moderate self-limiting application-site burning, pain, erythema, pruritus, papules, swelling, dryness, and hypertension. To manage local pain from capsaicin application, the skin is pre-treated with a local anesthetic such as topical lidocaine or an oral analgesic; a transient increase in pain is usually seen within 48 hours of patch application before the pain-relieving effect begins.

Without proper instruction on use, capsaicin can cause burning or stinging pain to the skin and, if ingested in large amounts by adults or small amounts by children, can produce nausea, vomiting, abdominal pain, and burning diarrhea. Eye exposure produces intense tearing, pain, conjunctivitis, and blepharospasm.

The more common potential adverse reactions and events with topical patch administration include local erythema, local pain, local pruritus, local edema, local swelling, local dryness, hypertension, papules, nausea, vomiting, nasopharyngitis, sinusitis, and bronchitis.

Gastrointestinal Toxicity at High Doses

Mucous membranes throughout the gastrointestinal tract from mouth to anus may be temporarily irritated by ingestion of capsaicin; in addition to irritation, diarrhea and vomiting may occur; capsaicinoids may produce severe gastritis and diarrhea; intragastric infusion of powdered red chillies caused a rapid and marked increase in the DNA content of the gastric aspirate, indicating exfoliation of the epithelial cells from the gastric mucosa.

A notable constraint in the therapeutic effects of capsaicin is its increased toxicity, especially in sensitive tissues.

Toxicity Threshold and Overdose

A study in mice has shown that based on LD50 values greater than 9 mg/kg (subcutaneous) or 190 mg/kg (by mouth), the likely mechanism of toxicity involves respiratory paralysis; there is no known reported case of an overdose in humans, and there is no known antidote.

Genotoxicity and Carcinogenicity Concerns

The Indian population consumes several-fold more chili than populations in other countries, yet this does not appear to adversely affect growth, organ weight, nitrogen balance, or blood chemistry; previous studies in animals and mammalian cell lines have not suggested any mutagenic effects of capsaicin in somatic cells or the germline. Nevertheless, epidemiological and laboratory data have suggested that capsaicin can act as a carcinogen or anticarcinogen, depending on context.

Potential Drug Interactions

Capsaicin appears to interact with xenobiotic-metabolizing enzymes, particularly microsomal cytochrome P450-dependent monooxygenases, which are involved in activation as well as detoxification of various chemical carcinogens and mutagens.

It is important to note that manufacturers have sponsored many of the studies examining the benefits of capsaicin; they often promote the agent for many disorders with little to no supporting evidence.

Special Considerations for the High-Dose Patch

In controlled clinical trials of Qutenza in neuropathic pain associated with postherpetic neuralgia, 75% of patients were 65 years and older and 43% were 75 years and older; the safety and effectiveness were similar in geriatric patients and younger patients.

The nature of administration and relatively high cost of capsaicin patches can significantly limit their use to a small number of patients with severe refractory symptoms.

References

• Mózsik G. (2009). Interdisciplinary review for correlation between capsaicinoids, NSAIDs, gastrointestinal mucosal damage and prevention in animals and humans. PubMed
• Fattori V, et al. (2020). Biological Properties, Bioactive Constituents, and Pharmacokinetics of Some Capsicum spp. and Capsaicinoids. PMC / International Journal of Molecular Sciences
• Zhang W, et al. (2024). Pharmacological activity of capsaicin: Mechanisms and controversies. PMC / International Journal of Molecular Medicine
• Petran M, et al. (2024). Capsaicin: Emerging Pharmacological and Therapeutic Insights. PMC
• Brederson J-D, et al. (2018). Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses. PMC / Molecules
• Fattori V, et al. (2014). Capsaicinoids in the treatment of neuropathic pain: a review. PMC / Therapeutic Advances in Neurological Disorders
• Lee K, et al. (2020). Ablation of TRPV1+ Afferent Terminals by Capsaicin Mediates Long-Lasting Analgesia for Trigeminal Neuropathic Pain. PMC / Frontiers in Molecular Neuroscience
• Anand P, Bley K. (2011). Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. PMC / British Journal of Anaesthesia
• Derry S, et al. (2016). Profile of the capsaicin 8% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability. PMC / Journal of Pain Research
• Argoff CE. (2012). Topical Capsaicin for Neuropathic Pain. PMC / Journal of Palliative Medicine
• Taghizadeh M, et al. (2021). The effect of Capsaicinoids or Capsinoids in red pepper on thermogenesis in healthy adults: A systematic review and meta-analysis. PubMed / Phytotherapy Research
• Hao Y, et al. (2022). Lipid-Lowering Efficacy of Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMC / Frontiers in Pharmacology
• Zheng J, et al. (2017). Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications. Bioscience Reports
• Smith SR, et al. (2010). Effects of dihydrocapsiate on adaptive and diet-induced thermogenesis with a high protein very low calorie diet: a randomized control trial. PMC / Nutrition and Metabolism
• Fernandes ES, et al. (2022). Capsaicin and TRPV1 Channels in the Cardiovascular System: The Role of Inflammation. PMC / Frontiers in Pharmacology
• Mohammadi-Sartang M, et al. (2018). A review of the effects of Capsicum annuum L. and its constituent, capsaicin, in metabolic syndrome. PMC / EXCLI Journal
• Adetunji CO, et al. (2022). Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer. PMC / Frontiers in Pharmacology
• Zhu J, et al. (2022). Beneficial effects of dietary capsaicin in gastrointestinal health and disease. PubMed / Journal of Gastroenterology
• Mózsik G, et al. (2019). Toxicokinetic Study of a Gastroprotective Dose of Capsaicin by HPLC-FLD Method. PMC / Molecules
• Palazzo E, et al. (2012). Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain. PMC / Pharmacological Reviews
• Hayman M, Kam PC. (2023). Capsaicin — StatPearls. NIH/NCBI Bookshelf
• Colpaert FC, et al. (2023). Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. PMC / Neurochemical Research
• Kennedy J, et al. (2021). Injectable Capsaicin for the Management of Pain Due to Osteoarthritis. PMC / Molecules
• FDA. (2020). QUTENZA® (capsaicin) patch — Prescribing Information. U.S. Food and Drug Administration
• Ren Z, et al. (2026). Capsaicin for cardiometabolic syndrome: multitarget mechanisms and therapeutic potential. Frontiers in Nutrition
• Hao L, et al. (2025). The effect of red pepper/capsaicin on cardiovascular risk factors: a systematic review, meta-analysis, and GRADE assessment. PubMed
• Persson MSM, et al. (2024). Efficacy and safety of topical capsaicin in the treatment of osteoarthritis pain: A systematic review and meta-analysis. Phytotherapy Research
• Bhave G, et al. (2012). Induction of TRPV1 desensitization by a biased receptor agonist. PMC / Journal of Neurochemistry
• Springer Nature. (2024). Capsaicinoids: From Natural Sources to Biosynthesis and their Clinical Applications. Springer
• Taylor & Francis. Capsaicinoids — Knowledge and References. Taylor & Francis Online